Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) [Phase 2]

View source ↗

Summary

A Phase 2 trial of vixarelimab for moderate-to-severe ulcerative colitis was terminated, with the study results posted on February 24, 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Vixarelimab (vixarelimab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Ulcerative Colitis | Phase 2 | Status: TERMINATED | Results posted: 2026-02-24